Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does RITUXIMAB-ARRX Cause Muscular weakness? 5 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Muscular weakness have been filed in association with RITUXIMAB-ARRX. This represents 1.4% of all adverse event reports for RITUXIMAB-ARRX.

5
Reports of Muscular weakness with RITUXIMAB-ARRX
1.4%
of all RITUXIMAB-ARRX reports
3
Deaths
5
Hospitalizations

How Dangerous Is Muscular weakness From RITUXIMAB-ARRX?

Of the 5 reports, 3 (60.0%) resulted in death, 5 (100.0%) required hospitalization, and 3 (60.0%) were considered life-threatening.

Is Muscular weakness Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for RITUXIMAB-ARRX. However, 5 reports have been filed with the FAERS database.

What Other Side Effects Does RITUXIMAB-ARRX Cause?

Product storage error (165) Circumstance or information capable of leading to medication error (116) Off label use (56) Intercepted product administration error (51) Accidental exposure to product (17) Intercepted product preparation error (16) Fatigue (14) Infusion related reaction (14) Drug ineffective (12) Dyspnoea (12)

What Other Drugs Cause Muscular weakness?

ADALIMUMAB (3,605) METHOTREXATE (2,813) RITUXIMAB (2,621) ATORVASTATIN (2,494) PREDNISONE (2,236) ETANERCEPT (2,207) DALFAMPRIDINE (1,916) TOCILIZUMAB (1,790) FINGOLIMOD (1,769) SECUKINUMAB (1,747)

Which RITUXIMAB-ARRX Alternatives Have Lower Muscular weakness Risk?

RITUXIMAB-ARRX vs RITUXIMAB-PVVR RITUXIMAB-ARRX vs RIVAROXABAN RITUXIMAB-ARRX vs RIVASTIGMINE RITUXIMAB-ARRX vs RIVOTRIL RITUXIMAB-ARRX vs RIZATRIPTAN

Related Pages

RITUXIMAB-ARRX Full Profile All Muscular weakness Reports All Drugs Causing Muscular weakness RITUXIMAB-ARRX Demographics